Multi-Drug Resistant Gram-Negative Sepsis in Neonates: The Special Role of Ceftazidime/Avibactam and Ceftolozane/Tazobactam.

Medicines (Basel, Switzerland) Pub Date : 2025-06-26 DOI:10.3390/medicines12030017

Niki Dermitzaki, Foteini Balomenou, Anastasios Serbis, Natalia Atzemoglou, Lida Giaprou, Maria Baltogianni, Vasileios Giapros

{"title":"Multi-Drug Resistant Gram-Negative Sepsis in Neonates: The Special Role of Ceftazidime/Avibactam and Ceftolozane/Tazobactam.","authors":"Niki Dermitzaki, Foteini Balomenou, Anastasios Serbis, Natalia Atzemoglou, Lida Giaprou, Maria Baltogianni, Vasileios Giapros","doi":"10.3390/medicines12030017","DOIUrl":null,"url":null,"abstract":"Neonatal sepsis is a major cause of morbidity and mortality in neonates. A particular concern is the increasing prevalence of antibiotic-resistant strains among neonatal intensive care units (NICUs). Two novel beta-lactam/beta-lactamase inhibitors have recently been approved for use in neonates with multidrug-resistant infections: ceftazidime/avibactam and ceftolozane/tazobactam. These agents demonstrate efficacy against a range of multidrug-resistant gram-negative pathogens, including extended-spectrum beta-lactamases (ESBL)-producing and carbapenem-resistant Enterobacterales, as well as multidrug-resistant Pseudomonas aeruginosa. This narrative review aims to summarize the current knowledge concerning the utilization of ceftazidime/avibactam and ceftolozane/tazobactam in the NICU. According to the existing literature, both agents have been shown to be highly effective with a favorable safety profile in the neonatal population.","PeriodicalId":74162,"journal":{"name":"Medicines (Basel, Switzerland)","volume":"12 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12286124/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicines (Basel, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/medicines12030017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Neonatal sepsis is a major cause of morbidity and mortality in neonates. A particular concern is the increasing prevalence of antibiotic-resistant strains among neonatal intensive care units (NICUs). Two novel beta-lactam/beta-lactamase inhibitors have recently been approved for use in neonates with multidrug-resistant infections: ceftazidime/avibactam and ceftolozane/tazobactam. These agents demonstrate efficacy against a range of multidrug-resistant gram-negative pathogens, including extended-spectrum beta-lactamases (ESBL)-producing and carbapenem-resistant Enterobacterales, as well as multidrug-resistant Pseudomonas aeruginosa. This narrative review aims to summarize the current knowledge concerning the utilization of ceftazidime/avibactam and ceftolozane/tazobactam in the NICU. According to the existing literature, both agents have been shown to be highly effective with a favorable safety profile in the neonatal population.

查看原文本刊更多论文

新生儿多重耐药革兰氏阴性脓毒症：头孢他啶/阿维巴坦和头孢托氮/他唑巴坦的特殊作用。

新生儿败血症是新生儿发病和死亡的主要原因。一个特别值得关注的问题是，在新生儿重症监护病房（NICUs）中，抗生素耐药菌株的流行率越来越高。两种新型β -内酰胺/ β -内酰胺酶抑制剂最近被批准用于患有多重耐药感染的新生儿：头孢他啶/阿维巴坦和头孢甲苯/他唑巴坦。这些药物证明对一系列多重耐药革兰氏阴性病原体有效，包括广谱β -内酰胺酶（ESBL）产生和碳青霉烯耐药肠杆菌，以及多重耐药铜绿假单胞菌。这篇叙述性综述旨在总结目前关于头孢他啶/阿维巴坦和头孢甲苯/他唑巴坦在新生儿重症监护室应用的知识。根据现有文献，这两种药物已被证明在新生儿人群中具有良好的安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medicines (Basel, Switzerland)

自引率

0.00%

发文量

审稿时长

6 weeks